Suzanne Ivie v. AstraZeneca Pharmaceuticals, LP

District Court, D. Oregon·Decided February 18, 2026·No. 3:19-cv-01657·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF OREGON

SUZANNE IVIE, Case No. 3:19-cv-01657-JR

Plaintiff, OPINION AND ORDER

v.

ASTRAZENECA PHARMACEUTICALS, LP,

Defendant. ____________________________ RUSSO, Magistrate Judge: Defendant AstraZeneca Pharmaceuticals moves for summary judgment pursuant to Fed. R. Civ. P. 56. For the reasons stated below, defendant’s motion is granted, and this case is dismissed. BACKGROUND1 The history of this matter is well known to the parties, such that it will only be repeated to the extent necessary to provide context for the present motion. Plaintiff Suzanne Ivie, a Utah resident, initiated this action in October 2019 for alleged

violations of Oregon state and federal employment law. Plaintiff initially asserted venue in Oregon was proper because defendant “conducts significant business in Oregon” and plaintiff “oversaw approximately eight Sales Representatives who worked on accounts in Utah, Idaho, and parts of Oregon” in her role as Executive District Sales Manager. First Am. Compl. ¶¶ 6, 4, 13 (doc. 35). Following the Court’s March 2021 summary judgment ruling (largely denying defendant’s motion), plaintiff’s discrimination and/or retaliation claims under the Age Discrimination in Employment Act, False Claims Act, Family Medical Leave Act, and state law claims remained. In the parties’ joint pretrial order, defendant provided general denials in regard to each of plaintiff’s state law claims but did not raise any specific issues concerning venue. Joint Pretrial Order 19-20 (doc. 66).

In June 2021, following a six-day jury trial, the jury ruled in favor of plaintiff solely in regard to her whistleblower retaliation claim under Or. Rev. Stat. § 659A.199, awarding $510,423 in economic damages and $1,872,000 in non-economic damages. Prior to the case being submitted to the jury, defendant moved for judgment as a matter of law under Fed. R. Civ. P. 50(a) on all state law claims, arguing Oregon’s statutes could not be applied extraterritorially to benefit a non-

1 To the extent defendant raises “evidentiary objections” in regard to plaintiff’s opposition, this Court is not bound by either party’s characterization of the evidence and instead independently reviews the record to determine whether summary judgment is appropriate. Def.’s Reply to Mot. Summ. J. 22-26 (doc. 286); Pl.’s Surreply 4-12 (doc. 289); Scott v. Harris, 550 U.S. 372, 380 (2007). resident because the evidence adduced at trial established that no wrongful conduct took place in Oregon. Defendant thereafter renewed its request for judgement as a matter of law under Fed. R. Civ. P. 50(b) and, alternatively, sought a new trial pursuant to Fed. R. Civ. P. 59. The Court granted

relief under Rule 50(b), vacated the jury verdict, and entered judgment in favor of defendant. Specifically, the Court rejected plaintiff’s arguments surrounding waiver and otherwise found she “failed to present facts required for the jury to find [in her favor] on the whistleblower protection claim,” and that “uphold[ing] the jury’s verdict would violate Oregon’s state law presumption against extraterritoriality [and] choice of law rules [as well as] the Fourteenth Amendment.” Ivie v. AstraZeneca Pharms., LP (“Ivie I”), 2021 WL 5167283, *1-5 (D. Or. Nov. 5, 2021), rev’d & remanded, 2023 WL 3563007 (9th Cir. May 19, 2023), cert. denied, 144 S. Ct. 495 (2023). On appeal, the Ninth Circuit reversed and remanded as follows: This case presents a straightforward matter of civil procedure. Ivie asserts that AstraZeneca forfeited or waived its “Oregon-nexus argument” by failing to raise it in the parties’ joint pretrial order or at any time prior to its initial JMOL motion brought at the close of Ivie’s case . . . We agree with Ivie [and] have repeatedly emphasized that a party may not offer evidence or advance theories at the trial which are not included in the pretrial order or which contradict its terms[.]

AstraZeneca’s frank admission that it failed to include the negative “Oregon-nexus” defense in the pretrial order resolves whether its Rule 50(b) motion raised a theory outside of the scope of that order . . . We reverse the district court’s order granting AstraZeneca’s renewed motion for judgment as a matter of law, and we remand with instructions for the court to consider in the first instance whether the company’s motion for new trial should be granted on the ground that the damages award was excessive.

Ivie I, 2023 WL 3563007 at *1-3 (citations and internal quotations, brackets, and ellipses omitted). The Ninth Circuit expressly declined to resolve whether “AstraZeneca’s failure [to raise its Oregon-nexus argument in the joint pretrial order] was a forfeiture or a waiver.” Id. at *1 n.1. Likewise, the Ninth Circuit did not reach the merits of defendant’s Oregon nexus defense; the only comment on the substantive aspects of the Court’s decision came from the dissent: Based on AstraZeneca’s pleadings, the district court concluded that Ivie had “adequate notice” of the defense—presumably meaning that Ivie would not be prejudiced by AstraZeneca’s raising of the defense in the Rule 50(b) motion. That doesn’t seem wrong—Ivie hasn’t proffered any additional evidence that she would have admitted at trial if she had more express notice of the extraterritorial defense. The district court’s ruling then seems to fall within its discretion [and on] the merits, the district court got it right. Id. at *3-4 (J. Bumatay, dissenting). On remand, the parties requested, and the Court granted, supplemental briefing surrounding defendant’s motion for a new trial. Defendant lodged its supplemental brief on January 24, 2024, asserting that a new trial was warranted because: (1) the jury determined “AstraZeneca would have discharged Ivie regardless of her alleged whistleblower activities,” such that “the $2.3 million damages award represents an unjust windfall”; (2) “the award of $1,872,000 for non-economic damages is grossly excessive and not supported by evidence”; and (3) plaintiff “fail[ed] to establish the Oregon nexus requirement for her state-law whistleblower claim.” Def.’s Suppl. Br. 4, 6, 8 (doc. 202). In response, plaintiff sought clarification surrounding the scope of briefing. Essentially, plaintiff relied on the rule of mandate for the proposition that the Ninth Circuit’s remand instructions effectively limited this Court’s discretionary authority under Rule 59. The Court ultimately instructed plaintiff “to address all issues raised in defendant’s supplemental brief,” highlighting the broad parameters of Rule 59 and the fact that the Ninth Circuit “did not resolve the substance of defendant’s Oregon nexus argument.” Order 5-6 (Apr. 17, 2024) (doc. 214). In October 2024, following oral argument and additional briefing, the Court granted defendant’s Rule 59 motion on the grounds that damages were excessive and not supported by the record. The Court also briefly addressed defendant’s Oregon nexus defense, noting the seeming lack of an Oregon nexus “underscore[s] the need for a new trial (as opposed to remittitur).” Ivie v. AstraZeneca Pharms., LP (“Ivie II”), 2024 WL 4553862, *13 (D. Or. Oct. 23, 2024) (internal citations and parentheticals omitted). Plaintiff subsequently moved for an interlocutory appeal. In February 2025, the Court

Free access — add to your briefcase to read the full text and ask questions with AI

Suzanne Ivie v. AstraZeneca Pharmaceuticals, LP, (D. Or. 2026).

Suzanne Ivie v. AstraZeneca Pharmaceuticals, LP (Suzanne Ivie v. AstraZeneca Pharmaceuticals, LP) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

§ 1292
28 U.S.C. § 1292